Temozolomide Acid
CAS No. 113942-30-6
Temozolomide Acid ( TMZA )
Catalog No. M22721 CAS No. 113942-30-6
Temozolomide Acid is a metabolite of temozolomide (TMZ). Temozolomide processes anticancer activity in vitro. Temozolomide (TMZ) is an oral alkylating agent used to treat glioblastoma multiforme (GBM) and astrocytomas.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
Size | Price / USD | Stock | Quantity |
50MG | 35 | In Stock |
|
100MG | 50 | In Stock |
|
200MG | 72 | In Stock |
|
500MG | Get Quote | In Stock |
|
1G | Get Quote | In Stock |
|
Biological Information
-
Product NameTemozolomide Acid
-
NoteResearch use only, not for human use.
-
Brief DescriptionTemozolomide Acid is a metabolite of temozolomide (TMZ). Temozolomide processes anticancer activity in vitro. Temozolomide (TMZ) is an oral alkylating agent used to treat glioblastoma multiforme (GBM) and astrocytomas.
-
DescriptionTemozolomide Acid is a metabolite of temozolomide (TMZ). Temozolomide processes anticancer activity in vitro. Temozolomide (TMZ) is an oral alkylating agent used to treat glioblastoma multiforme (GBM) and astrocytomas.
-
SynonymsTMZA
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number113942-30-6
-
Formula Weight195.14
-
Molecular FormulaC6H5N5O3
-
Purity>98% (HPLC)
-
SolubilityDMSO:Soluble; Water:Insoluble
-
SMILESCn1nnc2c(ncn2c1=O)C(O)=O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Lee S Y . Temozolomide resistance in glioblastoma multiforme[J]. Genes & Diseases, 2016, 3( 3):198-210.
molnova catalog
related products
-
R 892
Potent and selective bradykinin B1 receptor antagonist (ID50 values are 2.8 and > 600 nM at B1 and B2 receptors respectively). Exhibits no intrinsic agonist activity and is resistant to aminopeptidase and kininase II (ACE) cleavage. Displays hypertensive activity in vivo.
-
Tirzepatide TFA (202...
Tirzepatide TFA (LY3298176 TFA) is a disaccharide dependent insulin peptide (GIP) and glucagon-like peptide-1 (glp-1) receptor agonist.
-
AS 602801
AS 602801(Bentamapimod) is a novel, orally active inhibitor of JNK.